Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $118

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Evercore ISI Group analyst Daniel Markowitz maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and lowers the price target from $170 to $118.